What is the appropriate dosage and use of Propranolol (beta-blocker) for various medical conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Propranolol Dosage and Usage Guidelines for Various Medical Conditions

Propranolol dosing should be condition-specific, with cardiovascular conditions requiring 80-320 mg daily, infantile hemangiomas requiring 2-3 mg/kg/day, and careful monitoring for contraindications in all patients. 1, 2

Cardiovascular Indications

Hypertension

  • Initial dose: 80 mg once daily with extended-release capsules 2
  • Maintenance dose: 120-160 mg once daily 2
  • Maximum dose: Up to 640 mg daily may be required in some cases 2
  • Most of the antihypertensive effect is achieved with 80-160 mg daily doses 3

Angina Pectoris

  • Starting dose: 80 mg once daily with extended-release capsules 2
  • Gradual increase at 3-7 day intervals until optimal response 2
  • Average optimal dose: 160 mg once daily 2
  • Maximum recommended dose: 320 mg daily 2
  • For severe angina, higher doses (500-800 mg/day) may be needed 4

Arrhythmias

  • For stable narrow-complex tachycardias: 0.5-1 mg IV over 1 minute, repeated up to total dose of 0.1 mg/kg as needed 1
  • For atrial fibrillation/flutter rate control: Same IV dosing as above 1
  • Contraindicated in pre-excited atrial fibrillation/flutter 1

Post-Myocardial Infarction

  • Maintenance dose: 180-240 mg/day (based on serum drug levels) 5
  • Treatment duration: At least three years post-MI 5

Other Indications

Migraine Prophylaxis

  • Initial dose: 80 mg once daily with extended-release capsules 2
  • Effective dose range: 160-240 mg once daily 2
  • Discontinue if no response after 4-6 weeks at maximum dose 2

Infantile Hemangiomas

  • Starting dose: 1 mg/kg/day in three divided doses 1
  • Maintenance dose: 2 mg/kg/day in two or three divided doses 1
  • Maximum dose for non-responders: 3 mg/kg/day 1
  • For patients with PHACES syndrome: Start with 0.5 mg/kg/day 1
  • Treatment typically continues until 12-17 months of age 1

Hypertrophic Subaortic Stenosis

  • Usual dosage: 80-160 mg once daily with extended-release capsules 2

Administration Guidelines

  • Administer propranolol with food to reduce hypoglycemia risk 6
  • Hold doses during times of diminished oral intake or vomiting 6
  • For extended-release capsules, once-daily dosing is appropriate 2
  • When switching from tablets to extended-release capsules, retitration may be necessary 2

Monitoring and Precautions

Contraindications

  • Asthma or obstructive airway disease 1, 6
  • Second or third-degree heart block 1, 6
  • Decompensated heart failure 1, 6
  • Hypersensitivity to propranolol 1
  • Recent or ongoing hypoglycemic episodes 1

Monitoring Requirements

  • Baseline cardiovascular assessment before initiation 6
  • Monitor for hypotension, bradycardia, bronchospasm, and worsening heart failure 1, 6
  • For infantile hemangioma treatment: 1
    • Heart rate and blood pressure monitoring for 2-4 hours after first dose in high-risk infants
    • Glucose monitoring only in patients at risk of hypoglycemia (preterm, low weight, faltering growth)
    • No routine monitoring between appointments if the infant is well

Dose Adjustment

  • Lower doses required for patients with comorbidities 1, 6
  • For discontinuation, gradually reduce dosage over several weeks to prevent rebound effects 6, 2

Special Populations

Pediatric Patients with Infantile Hemangiomas

  • More cautious dosing for preterm infants or those with comorbidities 1
  • Patients with PHACES syndrome require brain MRI/MRA before full-dose treatment 1
  • Dose can be adjusted for weight at clinic visits 1

Patients with Cardiovascular Risk

  • Careful monitoring in patients with cardiac conditions 1, 6
  • Lower starting doses and more gradual titration in patients with heart failure risk 4

Remember that propranolol's effectiveness varies between individuals, and plasma concentration required for optimal effect can differ significantly between patients 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antihypertensive effect of propranolol at rest and during exercise.

British journal of clinical pharmacology, 1983

Research

Propranolol in the treatment of angina: a review.

Postgraduate medical journal, 1976

Guideline

Medication Transition from Flupentixol/Melitracen to Propranolol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.